Compare OEC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OEC | LCTX |
|---|---|---|
| Founded | 1862 | 1990 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 366.2M |
| IPO Year | 2014 | 1996 |
| Metric | OEC | LCTX |
|---|---|---|
| Price | $4.96 | $1.84 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $6.44 | $4.67 |
| AVG Volume (30 Days) | 776.7K | ★ 1.1M |
| Earning Date | 05-15-2026 | 06-05-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,806,700,000.00 | $14,556,000.00 |
| Revenue This Year | N/A | $6.32 |
| Revenue Next Year | $3.06 | $124.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $4.35 | $0.37 |
| 52 Week High | $14.13 | $2.09 |
| Indicator | OEC | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.82 | 52.67 |
| Support Level | $4.35 | $1.55 |
| Resistance Level | $5.43 | $1.84 |
| Average True Range (ATR) | 0.48 | 0.10 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 0.21 | 58.90 |
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.